Bluebird Bio Inc (BLUE) 136.26 $BLUE Is Legalized

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 2:56 PM

Bluebird Bio Inc (BLUE) 136.26 $BLUE

Is Legalized Marijuana or Gene Therapy the Better Emerging Industry?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:59AM CDT
The ability to spot powerful new technologies or industries early on can result in eye-popping returns for investors. The brave few that initially recognized the potential of Tesla Motors ' electric car, for example, have been richly rewarded over...
BLUE: 136.26 (-3.82), TSLA: 218.43 (-0.17), QURE: 26.09 (-0.28), GWPH: 121.00 (+0.23), CLDN: 13.68 (-0.26)

Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech
at The Street - Fri Apr 17, 4:59AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 136.26 (-3.82), XBIT: 22.94 (-4.50), ARIA: 9.71 (+0.10)

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.82 (-0.05), NBS: 2.91 (-0.14), OSIR: 16.33 (-0.26), BCLI: 4.14 (+0.02), MDVN: 131.01 (-1.50), INO: 10.35 (-0.25), CYTX: 0.99 (+0.01), STEM: 0.61 (-0.21), JUNO: 56.66 (-1.06), ATHX: 1.29 (-0.03), CUR: 1.94 (-0.06), BLUE: 136.26 (-3.82), VRTX: 133.20 (-2.62), AMGN: 167.91 (-1.26), KERX: 11.41 (-0.32), OMER: 24.32 (-0.35), KITE: 60.58 (-0.35), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16)

UniQure Deal Confirms Red-Hot Interest In Advanced Therapies
EP Vantage - at Seeking Alpha - Tue Apr 07, 3:42PM CDT
If there is any sign that pharma is beating the bushes to flush out promising advanced therapies, it is that Bristol-Myers Squibb (NYSE: BMY ) has shelled out $50m to license a preclinical gene therapy project that UniQure (NASDAQ: QURE ) ...
BLUE: 136.26 (-3.82), CLDN: 13.68 (-0.26), BMY: 65.80 (-0.20)

Another IPO Filed In Hot Cancer Immunotherapy Field
at Investor's Business Daily - Tue Apr 07, 12:55PM CDT
Adaptimmune Therapeutics has filed for an initial public offering, adding another company to one of the hottest sectors in the biotech field. U.K.-based Adaptimmune Therapeutics plans to raise up to $150 million and list on the Nasdaq under the...
BLUE: 136.26 (-3.82), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), AMGN: 167.91 (-1.26), JUNO: 56.66 (-1.06)

Why uniQure N.V. Stock Skyrocketed Today
George Budwell, The Motley Fool - Motley Fool - Mon Apr 06, 9:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the Dutch gene-therapy company uniQure ...
BLUE: 136.26 (-3.82), JNJ: 101.08 (+0.62), QURE: 26.09 (-0.28), PFE: 35.27 (-0.09), CLDN: 13.68 (-0.26), BMY: 65.80 (-0.20), NVS: 104.28 (-1.22)

3 Events That Could Sink the Biotech Sector This Year
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Apr 05, 8:06AM CDT
The biotech sector has been hot over the last few years, which naturally leads to talk of a biotech bubble. We asked our healthcare experts for potential events that might pop that bubble -- or at least let a little air out. While we're certainly...
BLUE: 136.26 (-3.82), IMS: 29.00 (+1.02), ESRX: 87.34 (+0.45), GILD: 103.69 (-1.52), CLDN: 13.68 (-0.26), ABBV: 66.07 (+1.82)

Celladon: The Next Breakthrough In Cardiovascular Gene Therapy?
DoconStocks - at Seeking Alpha - Tue Mar 31, 7:48AM CDT

BLUE: 136.26 (-3.82), ONCE: 61.39 (-0.66), CLDN: 13.68 (-0.26)

Intrexon and Merck Serono team up in cancer immunotherapy
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:05AM CDT

BLUE: 136.26 (-3.82), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), XON: 44.10 (-0.91), JUNO: 56.66 (-1.06)

Today's Review on Biotech Equities -- Biocept, Biogen Idec, Kite Pharma, Organovo Holdings, and Bluebird Bio
PR Newswire - Mon Mar 30, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BLUE: 136.26 (-3.82), BIIB: 401.71 (-28.57), KITE: 60.58 (-0.35), ONVO: 5.19 (+0.12), BIOC: 2.88 (-0.22)

1 Clinical-Stage Biotech Stock That Could Make You Into a Millionaire
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 7:06AM CDT
Biotech stocks have the ability to absolutely crush it in short order, turning even small investments into respectable sums of money. Investors that caught lightning in a bottle with Acadia Pharmaceuticals prior to the company releasing pivotal...
BLUE: 136.26 (-3.82), ACAD: 38.36 (-0.54), CLDN: 13.68 (-0.26)

Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 136.26 (-3.82), BIIB: 401.71 (-28.57), ESRX: 87.34 (+0.45), GILD: 103.69 (-1.52), PFE: 35.27 (-0.09), AMGN: 167.91 (-1.26)

Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy
at The Street - Wed Mar 25, 9:06AM CDT
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
BLUE: 136.26 (-3.82), ONCE: 61.39 (-0.66), CLDN: 13.68 (-0.26)

Mast Therapeutics: Investment Opportunity As Phase III Ongoing
Capital Screen - at Seeking Alpha - Fri Mar 20, 10:17AM CDT

BLUE: 136.26 (-3.82), MSTX: 0.49 (+0.01), GLYC: 8.82 (-0.14)

How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 136.26 (-3.82), QURE: 26.09 (-0.28), SGMO: 14.70 (-0.84), JUNO: 56.66 (-1.06), ATHX: 1.29 (-0.03), NVS: 104.28 (-1.22)

Juno Therapeutics Comments On Cancer Cure Lifts Group
at Investor's Business Daily - Thu Mar 19, 1:36PM CDT
Enthusiasm about potential cancer cures sent shares of Juno Therapeutics (JUNO) and its peers flying Thursday, though Juno's fourth-quarter earnings late Wednesday missed Wall Street estimates by a lot. "Within the next 12 months, we expect to have...
BLUE: 136.26 (-3.82), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), AMGN: 167.91 (-1.26), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)

CAR-T cancer therapy stocks head north
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 12:29PM CDT

BLUE: 136.26 (-3.82), ZIOP: 10.81 (-0.39), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), CNDO: 3.97 (-0.14), CLLS: 32.61 (-0.07), JUNO: 56.66 (-1.06)

CJS Global Complete Janitorial Solutions Expands Services to Central Florida, Signing on Many High-Profile Companies
PR Newswire - Thu Mar 19, 7:45AM CDT
CJS (Complete Janitorial Solutions) Global, founded by successful business owner Taylor Smith in Fort Lauderdale in March 2012, has recently expanded its services to the Orlando market. CJS is pleased to now provide services for renowned franchises in the Orlando, Tampa, Sarasota, Fort Myers, Daytona and Jacksonville areas, including Seasons 52, Dewey's Indoor Golf & Sports Grill, Roy's Hawaiian, Miller's Ale House Restaurant, Blue Martini, Kings Bowling Orlando, Taverna Opa, BRIO Tuscan Grille, Chili's and Bahama Breeze.
BLUE: 136.26 (-3.82)

Cellectis on deck for what should be a very strong IPO
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 9:42AM CDT

BLUE: 136.26 (-3.82), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), PFE: 35.27 (-0.09), CLLS: 32.61 (-0.07), JUNO: 56.66 (-1.06)

bluebird bio to Present at Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day
Business Wire - Wed Mar 18, 6:00AM CDT
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day on Wednesday, March 25, 2015 at 4:20 p.m. ET at the Metropolitan Club in New York City. bluebird bio will also participate in a panel titled, "Adoptive T-Cell Therapies: Considering Key Upcoming Clinical & Commercial Milestones" at 3:10 p.m. ET.
BLUE: 136.26 (-3.82)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Independents Finally Center Stage on Election Night

Unprecedented Spotlight on Independent Voters The political landscape is in for a shake-up, folks. Come November 3rd, we're witnessing something that hasn't been done before—an entire Election Night dedicated exclusively to independent voters. It’s high time these folks got the spotlight, considering a whopping 45% of U.S. adults have shunned the extremist seesaw of...

HIMS Lawsuit: Investors Under the Gun Before Deadline

HIMS Investors Find Themselves in Hot Water Well, it looks like the ball's in your court, folks. Hims & Hers Health, Inc. (NYSE: HIMS) has been caught in a whirlwind of legal drama, and if you're holding any $HIMS stock, you've got some decisions to make—and fast. With a looming November 2 deadline to step up in a securities class action, this is one of those...

Artprice Champions Creative Freedom with AI in 2026

AI and the Creative Reawakening As the autumn of 2026 rolls in, publishing circles are buzzing over artificial intelligence's role in artistry. Weekly updates hailing rejection, tolerance, or adaptation of AI in writing stir the pot. Yet, Artprice by Artmarket stands out by anchoring creative freedom and responsibility in the spotlight. Grounded on an initiative launched...

111, Inc. Strategizes with Advisors Amid Proposal Talks

Every time a company's board starts tossing around phrases like "strategic alternatives," you’ve got to pay closer attention. 111, Inc., holding the NASDAQ ticker YI, is one such entity at a crossroads. They've enlisted Houlihan Lokey China Limited as their independent financial advisor and Kirkland & Ellis as their U.S. legal counsel to sift through potential strategic...

American Water's $10K Grant Boosts Student Financial Skills

Financial Literacy: Building Skills for the Future When it comes to prepping kids for the real world, it's not just about packing their backpacks with textbooks and pencils; it's about arming them with the know-how to make smart financial moves. American Water Charitable Foundation's recent $10,000 grant to Junior Achievement of the Heartland is a shining example of the...

Metallium's U.S. Supply Chain Ambitions Hinge on Traxys MOU

Metallium and Traxys Partner to Boost U.S. Critical Metals Out there in Houston, October's cooked up a potential game-changer for U.S. critical metals supply like no one's business. Metallium Limited—those savvy cats juggling ASX and OTC markets—just laid down a non-binding Memorandum of Understanding (MOU) with Traxys North America LLC. The goal? To sharpen up and...

Govee's Retro Holiday Lights: A Festive Nostalgia Trip

Ah, the holidays—they're creeping up like a kid sneaking downstairs for a peek at their gifts. But it's not the gifts under the tree that brighten a room, it's those lights draping the tree itself. Enter Govee, bringing us back to that vintage glow we all remember from our childhoods. They've teamed up with Brady Tolbert, a design whiz who can make a living room look...

Mesirow Expands Retirement Reach with flexPATH Deal

Retirement Industry Shake-Up Here's the scoop: Mesirow's swinging big in the retirement scene with its latest acquisition of flexPATH's plan-level 3(38) business. In the world of outsourced fiduciarity—for thems ain't in the know—that's like bolting a turbocharger to an already darn good engine. Mesirow might just be strapping itself in for a wild ride in this 2026...

Sirha Lyon® 2027: A New Chapter in Foodservice

A Bold Step Forward There's a hearty aroma wafting from Lyon this January, and it's not just from the local gastronomy. Sirha Lyon® is queuing up for its 23rd edition, promising to turn the Foodservice and Hospitality sectors on their heads. Nearly 150,000 square meters of exhibition space packed to the rafters with over 4,300 exhibitors—this ain't your average trade...

Sinopec's Catalyst Conference: Driving Global Innovation

The Role of Catalysts in Modern Industry Swing by any bustling industrial hub, and you're likely to catch talk about catalysts—unsung heroes that make the machinery of modern industry run smoother, faster, and cleaner. Over in Tianjin, China, Sinopec just wrapped up its Second International Catalyst Customer Conference, which is less of a tongue-twister than it sounds....